CpG-Methylated Plasmid DNA Production for Tolerogenic Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing CpG-methylated plasmid DNA for gene therapy and DNA vaccination face challenges such as contamination, inconsistent methylation, and the need for time-consuming genetic engineering, making it difficult to achieve optimal methylation levels for therapeutic applications.
Innovation Solution
The development of E. coli strains with a chromosomal copy of a constitutive methylase gene, allowing for stable and controlled methylation of plasmid DNA to specific levels, enabling cost-effective and reproducible production of plasmid DNA for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If plasmid DNA is produced using conventional E. coli strains, then production cost is reduced, but CpG methylation levels are insufficient and inconsistent
Solution Approach 1:
The patent introduces a exo- methylase enzyme (SssI methylase) from another species into E. coli to catalyze CpG methylation of plasmid DNA. This parameter change in enzymatic activity enables consistent hypermethylation (≥60% methylation level) of CpG dinucleotides, resolving the methylation consistency issue while maintaining conventional production methods
Solution Approach 2:
The patent uses a plasmid-encoded methylase enzyme as an intermediary to transfer methyl groups to CpG dinucleotides in plasmid DNA during bacterial replication. This intermediary mechanism ensures consistent methylation without requiring complex genetic engineering of the host chromosome
2Manufacturing precision
If methylase gene is introduced as a plasmid to achieve CpG methylation, then methylation level increases, but plasmid contamination occurs
Solution Approach 1:
The patent extracts the methylase gene from the plasmid backbone and integrates it into the bacterial chromosome. This separation removes the harmful plasmid replication origin and selection markers that cause contamination, while retaining the useful methylase function through chromosomal integration
Solution Approach 2:
The patent segments the methylase gene from the plasmid structure and places it under the control of a constitutive promoter in the chromosomal DNA. This segmentation allows the methylase to be expressed as a standalone function without requiring plasmid maintenance, eliminating contamination risks
3Adaptability or versatility
If inducible promoter is used to control methylase expression, then expression can be controlled, but expression consistency varies
Solution Approach 1:
The patent inverts the promoter strategy by using a constitutive promoter instead of an inducible promoter. This inversion ensures continuous, consistent expression of the methylase enzyme throughout bacterial growth, eliminating variability introduced by induction timing and conditions while maintaining production efficiency
4Object-affected harmful factors
If CpG methylation is increased for therapeutic application, then immune response is reduced, but production complexity increases
Solution Approach 1:
The patent enables the E. coli production system to self-perform CpG methylation through the chromosomally-integrated methylase gene. The bacteria automatically methylate plasmid DNA during replication without requiring external intervention, achieving therapeutic-level hypermethylation while maintaining simple conventional production workflows
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the production of plasmid DNA with desired methylation levels, enhancing the efficacy of DNA vaccines and gene therapy by reducing immune response and increasing therapeutic expression duration, as demonstrated in treating autoimmune diseases and transplant rejection.
Implementation Method 1
DNA methylation in vertebrates typically occurs at CpG sites. This methylation results in the conversion of the cytosine to 5-methylcytosine. The formation of Me-CpG is catalyzed by the enzyme DNA methyltransferase.
Data Source
AI summary
The subject technology relates generally to compositions and methods for producing plasmid DNA of a desired quality. In addition, it relates to the discovery of Escherichia coli (E. coli) bacteria with a constitutive methylase gene stably incorporated into the chromosomal DNA and uses thereof.